olivLaw · US equity research
Herbalife Ltd. HLF
Wholesale-Drugs, Proprietaries & Druggists' Sundries · SIC 5122 · Vertical: Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
Herbalife is a global nutrition and wellness company that sells products through its network of independent members in a direct-selling model. With net sales of 5.0375 billion USD in 2025, it matters now because of four consecutive quarters of net sales growth and currency pressure on the 2026 outlook.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Herbalife Ltd. (HLF) stock was 15.31 USD (+6.47% on the day), with market capitalisation 1.6 bn USD, P/E 9.1 on diluted EPS of 1.68 USD over the last 12 months, dividend yield 1.96%, beta 0.88, 52-week range 8.24–19.96 USD. Latest reported quarter (Q3 2026): revenue of 1.4 bn USD (+6.0% YoY), net income of 58.8 m USD (+36.1% YoY), diluted EPS 0.55 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 71.5
- overbought (≥ 70)
- Bollinger (20, 2)
- 12.47 – 15.00
- above the upper band · %B 1.12 · band width 18.4%
- SMA 50 / 200
- 12.81 / 13.97
- mixed trend
- MACD (12, 26, 9)
- 0.34 / 0.27
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +22.5% | −1.1% | +23.6 pp | — |
| 3 months | +21.5% | −0.5% | +22.0 pp | — |
| 6 months | −6.9% | +4.4% | −11.3 pp | — |
| Year to date | +18.8% | +12.3% | +6.5 pp | — |
| 1 year | +91.9% | +13.5% | +78.3 pp | −4.3% |
| 3 years | +15.5% | +76.4% | −61.0 pp | +2.8% |
| 5 years | −64.6% | +63.7% | −128.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2 bn | 1.2 bn | 1.3 bn | 1.3 bn | 1.3 bn | 1.3 bn | 1.3 bn | 1.4 bn |
| Cost of revenue | 267.5 m | 265.2 m | 276.9 m | 284.2 m | 288.3 m | 291.1 m | 296.3 m | 306.1 m |
| Gross profit | 939.9 m | 956.5 m | 982.2 m | 989.5 m | 994.7 m | 1.0 bn | 1.0 bn | 1.0 bn |
| SG&A | 436.9 m | 431.9 m | 447.9 m | 447.6 m | — | — | — | — |
| Operating income | 106.5 m | 122.8 m | 132.6 m | 125.8 m | 99.8 m | 138.4 m | 128.3 m | 138.5 m |
| Depreciation & amortisation | 29.0 m | 30.7 m | 30.5 m ≈ | 30.7 m ≈ | 29.3 m | 29.4 m | 31.4 m ≈ | 30.5 m ≈ |
| Interest expense | 66.2 m | 52.0 m | 53.6 m | 51.0 m | 57.8 m | 46.8 m | 37.4 m | 31.9 m |
| Pre-tax income | 52.6 m | 70.8 m | 79.0 m | 74.8 m | 50.5 m | 91.6 m | -3.7 m | 106.6 m |
| Income tax | -125.3 m | 20.4 m | 29.8 m | 31.7 m | -34.6 m | 30.4 m | 22.8 m | 49.5 m |
| Net income | 177.9 m | 50.4 m | 49.3 m | 43.2 m | 85.4 m | 61.9 m | -26.3 m | 58.8 m |
| Diluted EPS | 1.74 ≈ | 0.49 | 0.48 | 0.42 | 0.81 ≈ | 0.57 | -0.25 | 0.55 |
| Operating cash flow | 69.6 m | 200.0 k | 96.0 m ≈ | 138.8 m ≈ | 98.3 m | 113.8 m | 32.9 m ≈ | 151.3 m ≈ |
| Capex | 25.7 m | 18.3 m | 22.8 m ≈ | 20.8 m ≈ | 18.5 m | 10.9 m | 11.3 m ≈ | 18.5 m ≈ |
| Share repurchases | 2.6 m | 2.2 m | 4.6 m ≈ | 1.3 m ≈ | 100.0 k | 700.0 k | 9.3 m ≈ | 200.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 45 percentile of its own 40-quarter history (min 2.7, median 10.1, max 50.7; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.9 bn | 4.9 bn | 5.5 bn | 5.8 bn | 5.2 bn | 5.1 bn | 5.0 bn | 5.0 bn |
| Revenue YoY | +10.5% | −0.3% | +13.6% | +4.7% | −10.3% | −2.7% | −1.4% | +0.9% |
| Net income | 296.6 m | 311.0 m | 372.6 m | 447.2 m | 321.3 m | 142.2 m | 254.3 m | 228.3 m |
| Net income YoY | +38.7% | +4.9% | +19.8% | +20.0% | −28.2% | −55.7% | +78.8% | −10.2% |
| Diluted EPS | 1.98 | 2.20 | 2.77 | 4.13 | 3.23 | 1.42 | 2.50 | 2.20 |
| Diluted EPS YoY | +53.5% | +11.1% | +25.9% | +49.1% | −21.8% | −56.0% | +76.1% | −12.0% |
| net % | 6.1% | 6.4% | 6.7% | 7.7% | 6.2% | 2.8% | 5.1% | 4.5% |
| Free cash flow | 564.4 m | 351.4 m | 516.6 m | 308.9 m | 196.1 m | 222.5 m | 163.4 m | 252.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 353.1 m USD
- Financial debt
- 2.0 bn USD
- Net debt
- 1.6 bn USD
- Equity
- -509.4 m USD
- Total assets
- 2.8 bn USD
- Debt / equity
- unavailable
- Current ratio
- 1.13x
- ROE
- unavailable
- ROA
- 8.3%
- FCF margin
- 5.0%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 5.5 bn | 5.8 bn | 5.2 bn | 5.1 bn | 5.0 bn | 5.0 bn | SEC (XBRL)· 18 Feb 2026verified |
| Cost of revenue | 1.2 bn | 1.2 bn | 1.2 bn | 1.2 bn | 1.1 bn | 1.1 bn | SEC (XBRL)· 18 Feb 2026verified |
| Gross profit | 4.4 bn | 4.6 bn | 4.0 bn | 3.9 bn | 3.9 bn | 3.9 bn | SEC (XBRL)· 18 Feb 2026verified |
| SG&A | 2.1 bn | 2.0 bn | 1.8 bn | 1.9 bn | 1.9 bn | — | SEC (XBRL)· 19 Feb 2025verified |
| Operating income | 640.6 m | 734.1 m | 545.2 m | 356.4 m | 385.9 m | 481.0 m | SEC (XBRL)· 18 Feb 2026verified |
| Depreciation & amortisation | 100.3 m | 107.6 m | 115.4 m | 113.3 m | 121.4 m | 121.2 m | SEC (XBRL)· 18 Feb 2026verified |
| EBITDA | 740.9 m ≈ | 841.7 m ≈ | 660.6 m ≈ | 469.7 m ≈ | 507.3 m ≈ | 602.2 m ≈ | SEC (XBRL)· 18 Feb 2026derived |
| Interest expense | 133.0 m | 153.1 m | 139.3 m | 165.9 m | 218.3 m | 214.4 m | SEC (XBRL)· 18 Feb 2026verified |
| Pre-tax income | 516.4 m | 560.8 m | 424.8 m | 203.0 m | 169.4 m | 275.1 m | SEC (XBRL)· 18 Feb 2026verified |
| Income tax | 143.8 m | 113.6 m | 103.5 m | 60.8 m | -84.9 m | 47.3 m | SEC (XBRL)· 18 Feb 2026verified |
| Net income | 372.6 m | 447.2 m | 321.3 m | 142.2 m | 254.3 m | 228.3 m | SEC (XBRL)· 18 Feb 2026verified |
| Diluted EPS | 2.77 | 4.13 | 3.23 | 1.42 | 2.50 | 2.20 | SEC (XBRL)· 18 Feb 2026verified |
| Weighted average diluted shares | 134.5 m | 108.3 m | 99.5 m | 100.2 m | 101.6 m | 103.6 m | SEC (XBRL)· 18 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 1.0 bn | 601.5 m | 508.0 m | 575.2 m | 415.3 m | 353.1 m | SEC (XBRL)· 18 Feb 2026verified |
| Inventories | 501.4 m | 575.7 m | 580.7 m | 505.2 m | 475.4 m | 511.7 m | SEC (XBRL)· 18 Feb 2026verified |
| Current assets | 1.8 bn | 1.4 bn | 1.4 bn | 1.4 bn | 1.1 bn | 1.1 bn | SEC (XBRL)· 18 Feb 2026verified |
| Property, plant & equipment, net | 390.2 m | 442.1 m | 486.3 m | 506.5 m | 460.2 m | 447.7 m | SEC (XBRL)· 18 Feb 2026verified |
| Goodwill | 100.5 m | 95.4 m | 93.2 m | 95.4 m | 87.7 m | 100.5 m | SEC (XBRL)· 18 Feb 2026verified |
| Intangibles (excl. goodwill) | 313.3 m | 317.3 m | 315.7 m | 314.0 m | 312.3 m | 315.1 m | SEC (XBRL)· 18 Feb 2026verified |
| Total assets | 3.1 bn | 2.8 bn | 2.7 bn | 2.8 bn | 2.7 bn | 2.8 bn | SEC (XBRL)· 18 Feb 2026verified |
| Accounts payable | 88.7 m | 92.0 m | 89.8 m | 84.0 m | 70.0 m | 99.8 m | SEC (XBRL)· 18 Feb 2026verified |
| Short-term debt | 22.9 m | 29.4 m | 29.5 m | 309.5 m | 283.5 m | 20.9 m | SEC (XBRL)· 18 Feb 2026verified |
| Long-term debt | 2.4 bn | 2.7 bn | 2.7 bn | 2.3 bn | 2.0 bn | 2.0 bn | SEC (XBRL)· 18 Feb 2026verified |
| Current liabilities | 1.1 bn | 1.1 bn | 976.6 m | 1.3 bn | 1.2 bn | 1.0 bn | SEC (XBRL)· 18 Feb 2026verified |
| Total liabilities | 3.9 bn | 4.2 bn | 4.0 bn | 3.9 bn | 3.5 bn | 3.3 bn | SEC (XBRL)· 18 Feb 2026verified |
| Equity | -856.1 m † | -1.4 bn † | -1.3 bn | -1.1 bn | -801.1 m | -509.4 m | SEC (XBRL)· 18 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 628.6 m | 460.3 m | 352.5 m | 357.5 m | 285.4 m | 333.3 m | SEC (XBRL)· 18 Feb 2026verified |
| Capex | 112.0 m | 151.4 m | 156.4 m | 135.0 m | 122.0 m | 80.4 m | SEC (XBRL)· 18 Feb 2026verified |
| Free cash flow | 516.6 m ≈ | 308.9 m ≈ | 196.1 m ≈ | 222.5 m ≈ | 163.4 m ≈ | 252.9 m ≈ | SEC (XBRL)· 18 Feb 2026derived |
| Investing cash flow | -123.2 m | -156.4 m | -156.2 m | -134.8 m | -84.6 m | -108.7 m | SEC (XBRL)· 18 Feb 2026verified |
| Financing cash flow | -320.9 m | -728.6 m | -264.7 m | -148.3 m | -335.3 m | -295.5 m | SEC (XBRL)· 18 Feb 2026verified |
| Share repurchases | 923.5 m | 1.0 bn | 146.7 m | 11.0 m | 8.3 m | 8.2 m | SEC (XBRL)· 18 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 56 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.6 bn USD
Key indicators
Coverage and freshness
Score by group
- Valuation95
- Balance sheet35
- Quality100
- Growth0
- Returns9
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 3.94 – 142.79 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)61.17 – 142.79 (Mid 87.05)WACC 6.6% · starting FCFF 462.7 m USD · terminal value share of EV 82%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: no growth between −30% and +40% justifies the price
- Peers: EV/EBITDA68.18 – 94.27 (Mid 87.80)4 companies used · median multiple 17.2x · quartiles 13.9x – 18.2xCAH, COR, MCK, NUS
- Peers: P/E45.32 – 53.70 (Mid 46.36)3 companies used · median multiple 27.5x · quartiles 26.9x – 31.9xCAH, COR, MCK
- Dividend discount (DDM)3.94 – 5.30 (Mid 4.52)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 56/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 3.4% | 100 (vs peers) | 7% |
| FCF conversion · Quality | 187.5% | 100 (on a fixed band) | 7% |
| Revenue CAGR 3Y · Growth | -1.1% | 0 (on a fixed band) | 10% |
| EPS CAGR 3Y · Growth | -12.0% | 0 (on a fixed band) | 10% |
| Net debt / EBITDA · Balance sheet | 2.4x | 45 (on a fixed band) | 12% |
| Interest coverage · Balance sheet | 2.9x | 22 (on a fixed band) | 7% |
| Current ratio · Balance sheet | 1.2x | 33 (on a fixed band) | 5% |
| P/E (TTM) · Valuation | 9.1x | 95 (on a fixed band) | 12% |
| EV/EBITDA · Valuation | 5.0x | 91 (on a fixed band) | 12% |
| FCF yield · Valuation | 21.0% | 100 (on a fixed band) | 10% |
| Shareholder yield (distributions) · Returns | 0.6% | 9 (on a fixed band) | 7% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet35/100 · 3/3 factors with a value
- Growth0/100 · 2/2 factors with a value
- Quality100/100 · 2/3 factors with a value
- Returns· partial9/100 · 1/2 factors with a value
- Valuation95/100 · 3/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
HERBALIFE LTD. (HLF). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 5.0 bn USD in 2025; YoY growth 0.9%; net margin 3.4%; net debt/EBITDA 2.4x.
The estimated value range is 53.24–73.99 USD per share (median of 4 methods, agreement: low); assumptions are illustrative. Against the central value of 66.71 USD, the price of 15.31 USD leaves a potential of 335.7% (value / price − 1) and a margin of safety of 77.0% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 56/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 3.4%
- FCF conversion: 187.5%
- P/E (TTM): 9.1x
- EV/EBITDA: 5.0x
- FCF yield: 21.0%
- The price is below the estimated value range
What contradicts it
- Revenue CAGR 3Y: -1.1%
- EPS CAGR 3Y: -12.0%
- Interest coverage: 2.9x
- Shareholder yield (distributions): 0.6%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): ROIC, Payout ratio (FCF).
Versus the vertical median
Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122) · same industry (4-digit SIC) · compared with 8 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| MCKMcKESSON CORPORATION | 123.5 bn | 27.5 | — | 1.1% | +12.4% | +21% / +127% |
| CORCencora, Inc. | 67.6 bn | 26.3 | 104.3% | 0.8% | +9.3% | −4% / +74% |
| CAHCardinal Health, Inc. | 60.9 bn | 36.2 | — | 0.7% | +14.2% | +23% / +145% |
| HLFHerbalife Ltd. | 1.6 bn | 9.1 | — | 3.4% | +0.9% | +92% / +15% |
| NUSNu Skin Enterprises, Inc. | 242.9 m | — | -32.5% | -15.7% | −14.3% | −50% / −71% |
| COSMCosmos Health Inc. | 33.0 m | — | -104.0% | -33.1% | +19.9% | −49% / −69% |
| HKPDCellyan Biotechnology Co., Ltd | 30.2 m | — | -0.6% | -0.1% | +21.7% | +87% / unavailable |
| ESYNHwh International Inc. | 11.6 m | — | -88.9% | -680.0% | −30.8% | −4% / −97% |
| MEDSDataMeds AI, Inc. | 4.6 m | — | — | -1,100.3% | +28.7% | −95% / unavailable |
1- and 3-year price returns: for HLF from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 8.69 Total return -43% · Per year -43% | 15.41 Total return 1% · Per year 1% | 23.27 Total return 52% · Per year 52% |
| 3 years | 7.51 Total return -51% · Per year -21% | 15.07 Total return -2% · Per year -1% | 25.13 Total return 64% · Per year 18% |
| 5 years | 6.50 Total return -58% · Per year -16% | 14.75 Total return -4% · Per year -1% | 27.13 Total return 77% · Per year 12% |
- Exit P/E± 3.77
- Net margin± 2.64
- Annual revenue growth± 2.29
- Annual dilution± 0.22
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Aug 2026; since then the company filed 8-K (02 Nov 2026 · results), 10-Q (02 Nov 2026).
In brief
Herbalife is a global nutrition and wellness company that sells products through its network of independent members in a direct-selling model. With net sales of 5.0375 billion USD in 2025 13, it matters now because of four consecutive quarters of net sales growth 3 and currency pressure on the 2026 outlook.
SWOT
Strengths
- The company has a global member network and a well-recognized product line with an established lead product 1.
- Net sales grew for four consecutive quarters, and cost management has been generally solid 3.
- The direct-selling model provides personal contact with customers that is hard for competitors to replicate 1.
Weaknesses
Opportunities
Risks
- Dependence on the member networkhigh
Sales depend almost entirely on independent members, and losing a large number of them could affect results 1.
- Regulation and the FTC Consent Orderhigh
Compliance with the FTC Consent Order and local rules may limit compensation changes and could bring sanctions 1.
- Currencymedium
A stronger dollar reduced reported revenue and led to a revised 2026 outlook 3.
- Energy and logistics costsmedium
Higher energy and transport prices could reduce margins if they cannot be passed on in prices 2.
- Concentration on one productmedium
One product accounts for a significant share of sales, and lower demand for it could affect results 1.
Investment thesis
What would need to be true (bull case)
What to watch
- Constant-currency net sales trendQ3 2026
- Delivery against the 2026 adjusted EBITDA guidance2026
- Adoption of Bioniq GO and Life I/O products2026
- CFO transition effective January 20272027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Aug 2026; since then the company filed 8-K (02 Nov 2026 · results), 10-Q (02 Nov 2026).
The business
Herbalife sells nutrition products through independent members who provide personalized coaching to their customers, using a direct-selling model worldwide 1. In 2025, weight management made up 54.5% of net sales and targeted nutrition 30.0% 1. The company has about 6.4 million members and operates in 95 markets 1.
The company's model relies on Members for substantially all sales, which allows one-on-one contact with customers 1. Member compensation is a significant operating expense and is recorded within selling expenses 1.
In China the company sells through independent service providers and sales representatives, reflecting local regulation 1. This structure differs from its model elsewhere 1.
Segments
Market context
Trends
- Personalized nutritiontailwind
The launch of Bioniq GO and the Pro2col platform suggests personalization could become a differentiator if member adoption grows 3. The effect depends on execution and consumer acceptance.
- Obesity and interest in fitnesstailwind
The company links its growth to trends such as the obesity epidemic and interest in healthy, active living 1. These trends could support long-term demand.
- Currency and inflationheadwind
A stronger dollar created currency headwinds in the second quarter and led to a revised reported outlook 3. Inflation and energy prices may raise production and logistics costs 2.
- Regulation and the direct-selling modelmixed
The FTC Consent Order and marketing rules may limit changes to the compensation plan and affect the member network 1. The effect is mixed: it protects stability but restricts flexibility.
Competitive position
The company competes in nutrition with firms such as BellRing Brands, The Hain Celestial Group, Nestlé and The Simply Good Foods Company 1. In direct selling, competitors include Medifast, Nu Skin, USANA and Amway 1. It also competes for member recruitment 1.
The company says its edge is daily consumption through Nutrition Clubs and Daily Methods of Operation, which aim to build customer loyalty 1. It acknowledges it cannot exert the same control over members as over employees 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Herbalife (HLF) Bets $250M On Its Own Battered StockYahoo Finance — News · 15 Sept 2026 · EN
- [P] Romeo Căzănescu (Herbalife): ”Românii sunt azi mult mai orientați către prevenție și wellbeing decât în urmă cu un deceniu”HotNews.ro · 03 Sept 2026 · RO
- Generative AI Is Having Its Herbalife MomentHacker News · 19 Jun 2026 · EN
The latest news item in our archive is from 15 Sept 2026; the newest SEC filing is from 02 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report02 Nov 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report02 Nov 2026
- Current report31 Aug 2026Departure or appointment of officers
- Current report05 Aug 2026Results of operations · Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report05 Aug 2026
- Current report06 May 2026Results of operations · Shareholder vote · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report06 May 2026
- Current report01 May 2026Material agreement · Creation of a direct financial obligation · Item 2.04 · Other events · Financial statements and exhibits
- Current report16 Apr 2026Other events · Financial statements and exhibits
- Current report14 Apr 2026Results of operations · Other events · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Herbalife Ltd. · 18 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Herbalife Ltd. · 05 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Herbalife Ltd. · 05 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.